Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Background/Aims: Diffuse large B-cell lymphoma (DLBCL) in Koreans is frequently accompanied by extranodal (EN) disease at the time of autologous stem cell transplantation (ASCT). We sought to determine whether high EN involvement affected survival following ASCT in Koreans. Methods: We reviewed 27 patients who had DLBCL with residual disease at ASCT: 13 with residual disease at nodal site(s) only and 14 with nodal and EN disease. Results: Univariate analysis showed that disease status, lactate dehydrogenase (LDH), and performance status at ASCT were predictors of survival following ASCT. The number of EN sites, as categorized by the International Prognostic Index system, had no prognostic significance. When EN involvement at ASCT was classified as negative or positive, the 2-year overall survival for the negative group was 64%, significantly better than the 14% for the positive group (p=0.021), and the event-free survival for the negative group was 62%, significantly better than the 14% for the positive group (p=0.02). Conclusions: Patients who had DLBCL with residual EN involvement at ASCT showed worse outcomes following ASCT compared to those without EN disease.
Abstract
Background/Aims: Diffuse large B-cell lymphoma (DLBCL) in Koreans is frequently accompanied by extranodal (EN) disease at the time of autologous stem cell transplantation (ASCT). We sought to determine whether high EN involvement affected survival following ASCT in Koreans. Methods: We reviewed 27 patients who had DLBCL with residual disease at ASCT: 13 with residual disease at nodal site(s) only and 14 with nodal and EN disease. Results: Univariate analysis showed that disease status, lactate dehydrogenase (LDH), and performance status at ASCT were predictors of survival following ASCT. The number of EN sites, as categorized by the International Prognostic Index system, had no prognostic significance. When EN involvement at ASCT was classified as negative or positive, the 2-year overall survival for the negative group was 64%, significantly better than the 14% for the positive group (p=0.021), and the event-free survival for the negative group was 62%, significantly better than the 14% for the positive group (p=0.02). Conclusions: Patients who had DLBCL with residual EN involvement at ASCT showed worse outcomes following ASCT compared to those without EN disease.
참고문헌 (30)
- Appelbaum FR, "Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma", Blood, 52, pp.85~95 (1978)
- Moskowitz CH, "The International Prognostic Index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma", BONE MARROW TRANSPLANTATION, 23, pp.561~567 (1999)
- Philip T, "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma", New England Journal of Medicine, 333, pp.1540~1545 (1995)
- Colombat P, "The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin's lymphomas", JOURNAL OF CLINICAL ONCOLOGY, 8, pp.630~637 (1990)
- Lazarus HM, "High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma", JOURNAL OF CLINICAL ONCOLOGY, 10, pp.1682~1689 (1992)
- Vose JM, "High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma", JOURNAL OF CLINICAL ONCOLOGY, 11, pp.1846~1851 (1993)
- Wheeler C, "Prognostic factors for treatment outcome in autotransplantation of intermediategrade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide", JOURNAL OF CLINICAL ONCOLOGY, 11, pp.1085~1091 (1993)
- Mills W, "BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma", JOURNAL OF CLINICAL ONCOLOGY, 13, pp.588~595 (1995)
- Petersen FB, "Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle", JOURNAL OF CLINICAL ONCOLOGY, 8, pp.638~647 (1990)
- Rapoport AP, "ASCT for DLBCL with residual EN 189 Flesher WR, Kouides PA, DiPersio JF, Rowe JM. Autotransplantation for relapsed or refractory non-Hodgkin's lymphoma (NHL): long-term follow-up and analysis of prognostic factors", BONE MARROW TRANSPLANTATION, 19, pp.883~890 (1997)
- Phillips GL, "The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation", Blood, 75, pp.831~838 (1990)
- Weaver CH, "High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma", JOURNAL OF CLINICAL ONCOLOGY, 12, pp.2559~2566 (1994)
- The International Non-Hodgkin's Lymphoma Prognostic Factors Project, "predictive model for aggressive non-Hodgkin's lymphoma", New England Journal of Medicine, 329, pp.987~994 (1993)
- Hamlin PA, "Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma", Blood, 102, pp.1989~1996 (2003)
- Caballero MD, "BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors", BONE MARROW TRANSPLANTATION, 20, pp.451~458 (1997)
- Intragumtornchai T, "CHOP versus CHOP plus ESHAP and high-dose therapy with autologous peripheral blood progenitor cell transplantation for high-intermediate-risk and high-risk aggressive non-Hodgkin's lymphoma", Clinical Lymphoma, 1, pp.219~225 (2000)
- Blay J, "The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial", Blood, 92, pp.3562~3568 (1998)
- Fanin R, "Autologous stem cell transplantation for aggressive non-Hodgkin's lymphomas in first complete or partial remission: a retrospective analysis of the outcome of 52 patients according to the age-adjusted International Prognostic Index", BONE MARROW TRANSPLANTATION, 21, pp.263~271 (1998)
- Nademanee A, "Results of high-dose therapy and autologous bone marrow", stem cell transplantation during remission in poor-risk intermediate and high-grade lymphoma: International Index high and high-intermediate risk group, 1997, pp.90, 3844~3852
- Ko YH, "REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features", Cancer, 83, pp.806~812 (1998)
- Cheolwon Suh, "Prognostic Factors in Non-Hodgkin’s Lymphoma Patients Treated by Autologous Stem Cell Transplantation: A Single Center Experience", Cancer Research and Treatment, 37(5), pp.294~301 (2005), 대한암학회
- Cheson BD, "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas", JOURNAL OF CLINICAL ONCOLOGY, 17, pp.1244~ (1999)
- Vose JM, "Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry", JOURNAL OF CLINICAL ONCOLOGY, 19, pp.406~413 (2001)
- The Non-Hodgkin's Lymphoma Classification Project, "National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage", Cancer, 49, pp.2112~2135 (1982)
- Harris NL, "Bloomfield CD. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting: Airlie House, Virginia, November 1997", JOURNAL OF CLINICAL ONCOLOGY, 17, pp.3835~3849 (1999)
- Lee JL, "ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF", BONE MARROW TRANSPLANTATION, 35, pp.449~454 (2005)
- Pfreundschuh M, "Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL", Blood, 104, pp.626~633 (2004)
- Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma", New England Journal of Medicine, 346, pp.235~242 (2002)
- Caballero MD, "High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group", ANNALS OF ONCOLOGY, 14, pp.140~151 (2003)
- Rodriguez J, "Autologous stem-cell transplantation in diffuse large B-cell non-Hodgkin's lymphoma not achieving complete response after induction chemotherapy: the EL", TAMO experience, 2004, pp.15, 1504~1509